Table 2. . Median overall survival for eflornithine–procarbazine, lomustine, vincristine versus procarbazine, lomustine, vincristine for anaplastic glioma patients from 2002, 2009 and 2012 analyses.
| Year | Path | Eflornithine–PCV mOS, months (95% CI) | PCV mOS, months (95% CI) | Eflornithine–PCV benefit, months | OS hazard ratio (95% CI) | Log-rank p-value | Gehan–Breslow–Wilcoxon test p-value | PFS hazard ratio (95% CI) | Log-rank p-value |
|---|---|---|---|---|---|---|---|---|---|
| 2002† | AG | 79 | 64 | 15 | 0.7 (0.5–1.1) | 0.13 | 0.03 | 0.7 (0.5–1.0) | 0.07 |
| 2002† | AA | 71 | 46 | 25 | 0.7 (0.5–1.0) | 0.08 | 0.04 | 0.7 (0.5–1.4) | 0.08 |
| 2009 | AG | 85 (60, 135) | 61 (35, 90) | 24 | 0.7 (0.5–1.0) | 0.08 | 0.04 | – | – |
| 2009 | AA/AOA | 85 (57, 132) | 52 (28, 85) | 33 | 0.7 (0.5–1.1) | 0.11 | 0.07 | – | – |
| 2012 | AG | 85 (60, 150) | 61 (34, 90) | 24 | 0.8 (0.5–1.1) | 0.10 | 0.05 | – | – |
| 2012 | AA | 76 (55, 130) | 42 (25, 85) | 34 | 0.7 (0.5–1.1) | 0.09 | 0.05 | – | – |
| 2012 | AA/AOA | 85 (60, 150) | 52 (30, 88) | 33 | 0.8 (0.5–1.1) | 0.12 | 0.07 | – | – |
The method of Brookmeyer–Crowley was used to estimate the 95% CI for the median values in the table [31].
†From publication [8].
AA: Anaplastic astrocytoma; AG: Anaplastic glioma; AOA: Anaplastic oligoastrocytoma; mOS: Median overall survival; OS: overall survival; PCV: Procarbazine, lomustine, vincristine; PFS: Progression-free survival.